Literature DB >> 25689805

Amitriptyline/Ketamine as therapy for neuropathic pruritus and pain secondary to herpes zoster.

John R Griffin, Mark D P Davis.   

Abstract

Frequent causes of morbidity secondary to herpes zoster include acute pain, secondary infection, and postherpetic neuralgia. A less documented complication is pruritus, which can be either acute or postinfectious when it persists more than 3 months after the rash has healed. We discuss a case of severe, acute neuropathic pruritus and pain secondary to active herpes zoster that was unresponsive to standard medical therapy, including oral antihistamines, topical lidocaine, oral gabapentin, and local wound care. Modest control of the pruritus and pain was achieved with continued multimodal therapy and the addition of topical 2% amitriptyline/0.5% ketamine gel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25689805

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  5 in total

Review 1.  [Neuropathic pruritus-Evidence-based treatment recommendations].

Authors:  Panoraia Baka; Frank Birklein
Journal:  Nervenarzt       Date:  2022-08-11       Impact factor: 1.297

2.  NMDA receptor antagonists attenuate intrathecal morphine-induced pruritus through ERK phosphorylation.

Authors:  Le Shen; Weijia Wang; Siyu Li; Jing Qin; Yuguang Huang
Journal:  Mol Brain       Date:  2018-06-28       Impact factor: 4.041

Review 3.  The Neuromodulatory Effect of Antipruritic Treatment of Chronic Prurigo.

Authors:  Claudia Zeidler; Manuel Pereira; Sonja Ständer
Journal:  Dermatol Ther (Heidelb)       Date:  2019-09-11

4.  Postherpetic Pruritus: A Potential Complication of Herpes Zoster Virus Infection.

Authors:  Shahzeb Hassan; Philip R Cohen
Journal:  Cureus       Date:  2019-09-16

5.  The relative frequency of pruritus in postherpetic neuralgia patients presenting to the pain clinic and associative factors.

Authors:  Cheolhwan Park; Hyunji John; Jaemoon Lee; Seungwan Hong; Minjung Kim; Sangtae Park; Jae Hun Kim
Journal:  Medicine (Baltimore)       Date:  2022-09-02       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.